Many HCV revenue models include breakouts for the treatment-experienced population. Where do the size estimates for this population come from? An estimate of this population size would be quite difficult, given cures, serial retreatments, and mortality.
There are so many holes in many analysts HCV modeling assumptions that I basically stop commenting on them. GS and WF are better ones that you at least can see where conservative and reasonable assumptions lead to.
Market Data 
Markets 
AI
